Harvard Bioscience Inc

NAS:HBIOHealthcarenasdaq_composite

$8.25−1.08%LiveIn session · ≈ AED 30.30 · Market cap $37.56M · Next earnings Thu 5 Nov

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	56.8%	56.9%	53.7%	58.9%	58.2%	53.0%	—	—
Operating margin	0.2%	1.7%	−6.1%	1.7%	−6.6%	−0.7%	−0.7%	+0.0 pts
Net margin	−7.6%	−0.2%	−8.4%	−3.0%	−13.2%	−65.5%	−65.5%	+0.0 pts
EBITDA margin	5.1%	7.6%	0.8%	7.2%	−1.6%	−53.8%	—	—
Return on equity	−10.2%	−0.3%	−13.2%	−4.7%	−19.6%	−412.8%	−412.8%	+0.0 pts
Return on assets	−5.0%	−0.2%	−6.5%	−2.5%	−9.8%	−70.8%	−70.8%	+0.0 pts
Return on capital employed	0.2%	1.5%	−5.7%	1.7%	−8.7%	−1.1%	—	—
Debt / equity	0.8×	0.7×	0.8×	0.6×	0.7×	3.2×	3.2×	+0.0%
Debt / assets	36.9%	35.1%	37.3%	31.1%	35.1%	55.3%	—	—
Interest coverage	0.0×	1.3×	−2.7×	0.5×	−1.9×	−0.1×	—	—
Current ratio	2.5×	2.4×	2.2×	1.8×	0.8×	2.2×	2.2×	+0.0%
Quick ratio	1.4×	1.3×	1.1×	0.9×	0.4×	1.2×	—	—
Cash ratio	0.4×	0.3×	0.2×	0.2×	0.1×	0.4×	0.4×	+0.0%
Asset turnover	0.7×	0.7×	0.8×	0.8×	0.7×	1.1×	—	—
Inventory turnover	2.0×	1.9×	2.0×	1.9×	1.7×	2.0×	—	—
Receivables turnover	5.7×	5.4×	6.8×	7.0×	6.3×	5.4×	—	—
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—

Margins, returns, leverage and liquidityUpdated 31 Dec 2025 ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.